Cartilage repair Glendale: help for a knee that stays sore

What may calm the knee today?

Cold may calm the knee when it swells after an outing. Warmth before getting up may make early stiffness easier.

A cane can take some strain off the sore side. Ask your doctor whether a brace or medicine fits with your other care.

Check the knee again the next morning, not only after the walk. Tell your doctor if the same errand keeps bringing back swelling.

Why can one damaged spot hurt?

Cartilage is the smooth cover where the knee bones meet. A chondral defect means that cover has one worn or torn spot.

An osteochondral defect goes through the cover and into the bone below. Arthritis spreads wear farther and often brings stiffness with a steady ache.

When is an exam worth making?

Make an appointment when normal errands cause soreness or swelling again. Catching, locking or sudden buckling also calls for an exam.

A warm, swollen knee needs prompt medical care when fever starts. After an injury, seek quick help if standing on that leg isn't possible.

What if the knee doesn't settle?

At its Phoenix-area clinics, QC Kinetix offers regenerative treatments made from parts of your blood. Medical providers draw the blood and prepare concentrated platelet-rich plasma for the sore joint.

This plasma holds extra platelets, tiny blood pieces that help clotting. Ask whether the aim is less soreness or easier walking, and how they'll check.

Sources

1. A JBJS evidence-based review of chondral lesions of the knee sets management by lesion size, location, limb alignment and rotation, and patient demand rather than by product: osteochondral autograft transfer is described as durable and predictable for smaller lesions (under 2 cm2) in young active patients, while lesions of 2 cm2 or more are typically treated with osteochondral allograft transplantation, particulated juvenile articular cartilage, or matrix-associated chondrocyte implantation, with favourable mid- and long-term results reported for allograft or MACI in large lesions of 3 cm2 or more.

   Dekker TJ, et al. — Chondral Lesions of the Knee: An Evidence-Based Approach.. J Bone Joint Surg Am, 2021. DOI: 10.2106/JBJS.20.01161.

2. FDA biologics licence BL 125603 (Vericel) describes MACI verbatim as "an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults." The licensed indication is a two-stage surgical implantation for full-thickness DEFECTS of the knee in adults. It is not an injection, it is not licensed for osteoarthritis, and it is not licensed for any joint other than the knee.

   U.S. Food and Drug Administration — MACI (autologous cultured chondrocytes on porcine collagen membrane). FDA, Center for Biologics Evaluation and Research, 2024.

3. In the SUMMIT randomised trial, 144 patients with at least one symptomatic Outerbridge grade III-IV knee defect of 3 cm2 or more (mean lesion 4.8 cm2, mean age 33.8) were randomised to MACI or microfracture. At two years, improvements in KOOS pain (37.0 to 82.5 versus 35.5 to 70.9) and function (14.9 to 60.9 versus 12.6 to 48.7) were significantly greater with MACI.

   Saris D, et al. — Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective Randomized Trial.. Am J Sports Med, 2014. DOI: 10.1177/0363546514528093.

4. At five years, 128 of the 144 SUMMIT patients remained in follow-up and MACI's advantage over microfracture on the co-primary KOOS pain and function endpoint was maintained and remained statistically significant (P = .022), with activities of daily living also significantly better (P = .007).

   Brittberg M, et al. — Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Five-Year Follow-up of a Prospective Randomized Trial.. Am J Sports Med, 2018. DOI: 10.1177/0363546518756976.

5. At 14 to 15 years, the Norwegian multicentre randomised trial of 80 patients with a single symptomatic femoral condyle cartilage defect found no significant difference between autologous chondrocyte implantation and microfracture on any clinical scoring system. There were 17 failures in the ACI group versus 13 after microfracture, and more total knee replacements had been needed after ACI (6 versus 3).

   Knutsen G, et al. — A Randomized Multicenter Trial Comparing Autologous Chondrocyte Implantation with Microfracture: Long-Term Follow-up at 14 to 15 Years.. J Bone Joint Surg Am, 2016. DOI: 10.2106/JBJS.15.01208.

6. The ACTIVE randomised trial assigned 390 patients aged 18-55 whose previous cartilage surgery had failed to autologous chondrocyte implantation or alternative surgical management. At five years there was NO evidence of a difference in Lysholm score (2.9 points, 95% CI -1.8 to 7.5; P = .46), about 55% were still experiencing benefit in the ACI arm, time to cessation of benefit was similar, and significantly more participants had a serious adverse event with ACI (P = .02). Previous marrow stimulation had a detrimental effect on ACI outcome.

   Snow M, et al. — A Randomized Trial of Autologous Chondrocyte Implantation Versus Alternative Forms of Surgical Cartilage Management in Patients With a Failed Primary Treatment for Chondral or Osteochondral Defects in the Knee.. Am J Sports Med, 2023. DOI: 10.1177/03635465221141907.

7. At ten years the same 390-patient ACTIVE trial found the ACI arm scored significantly higher on Lysholm (mean difference 7.3 points, 95% CI 2.5 to 12.1), while ten-year treatment failure rates were comparable at 29% versus 25% (HR 1.04). A sensitivity analysis accounting for later operations reduced the advantage to 3.8 points (95% CI -1.8 to 9.5). The five-year and ten-year readouts of the same trial point in different directions, which is why a single follow-up point should never be quoted alone.

   Snow M, et al. — Ten year follow-up of a randomized trial of autologous chondrocyte implantation versus alternative forms of surgical cartilage management in the knee.. Osteoarthritis Cartilage, 2026. DOI: 10.1016/j.joca.2026.03.112.